A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (NCT06742723)
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants With Chronic Kidney Disease and High Blood Pressure
🩺 Plain-English Summary (8th-Grade Level)
International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure
Who can join: Review the eligibility criteria below.
Location: Research Site — Fairhope, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (771 Sites)
Showing the first 25 of 771 sites.
- Research Site — Fairhope, Alabama
- Research Site — Surprise, Arizona
- Research Site — Tucson, Arizona
- Research Site — Beverly Hills, California
- Research Site — Canoga Park, California
- Research Site — Concord, California
- Research Site — Fremont, California
- Research Site — Fullerton, California
- Research Site — Inglewood, California
- Research Site — Los Alamitos, California
- Research Site — Los Angeles, California
- Research Site — San Diego, California
- Research Site — San Francisco, California
- Research Site — Stanford, California
- Research Site — Tarzana, California
- Research Site — Arvada, Colorado
- Research Site — Denver, Colorado
- Research Site — New Britain, Connecticut
- Research Site — Washington D.C., District of Columbia
- Research Site — Boca Raton, Florida
- Research Site — Boynton Beach, Florida
- Research Site — Edgewater, Florida
- Research Site — Fort Lauderdale, Florida
- Research Site — Hollywood, Florida
- Research Site — Jacksonville Beach, Florida
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Kidney Disease and Hypertension
- A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. — Fairhope, Alabama
- A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. — Surprise, Arizona
Explore by condition: All Chronic Kidney Disease and Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.